Moreover, the results of a phase II study showed that the combination of Tremelimumab (anti-CTLA-4) with Durvalumab (anti-PD-L1) could increase the overall survival (OS) of patients with advanced refractory CRC [120]. The gene discussed is CTLA4; the disease is colorectal carcinoma.